GleamWall
中文EN

SER Serina Therapeutics, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1708599 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY132.1%
TTM net income YoY-72.2%
TTM EPS YoY-26.5%
Revenue 3-yr CAGR56.4%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-18,478.5%
Net margin-14,755.4%
FCF margin-13,856.9%
EBITDA margin-18,439.2%

Returns

ROE-6,351.7%
ROA-280.5%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets100.5%
Debt / equity—
Current ratio1.71x
Interest coverage-112.78x

Cash quality & payout

Operating cash flow / net income0.94x
Accruals ratio-17.9%
Payout ratio—
Capex / revenue45.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$125,000$0—$0$0$130,000$0-$14,000
R&D expense$4.63M$3.82M$3.20M$3.40M$3.65M$3.15M$2.95M$2.37M
SG&A expense$3.36M$2.97M$3.08M$2.81M$2.74M$2.54M$2.91M$3.17M
Operating income-$7.86M-$6.78M—-$6.21M-$6.39M-$5.57M-$5.86M-$5.55M
Interest expense$204,000$203,000$189,000$198,000$6,000$9,000$0$17,000
Pretax income——-$6.89M———-$4.82M—
Income tax——$7,000———$0—
Net income-$7.91M-$6.36M-$6.90M-$3.34M-$4.58M-$6.45M-$4.81M-$2.74M
EBITDA-$7.84M-$6.75M—-$6.16M-$6.39M-$5.57M-$5.86M-$5.59M
EPS (basic)-0.31-0.55-0.58—-0.45-0.66-0.49—
EPS (diluted)-0.31-0.55-0.58—-0.45-0.66-0.49—
Weighted avg. shares (diluted)25.41M16.39M12.05M—10.34M10.00M9.76M—
Balance sheet
Cash & equivalents$19.40M$23.02M$24.53M$3.06M$8.62M$6.04M$4.27M$3.67M
Current assets$20.93M$25.03M$26.47M$6.08M$11.50M$7.99M$5.75M$5.68M
PP&E, net$466,000$482,000$472,000$465,000$580,000$588,000$484,000$501,000
Total assets$21.87M$25.81M$27.30M$6.95M$12.41M$8.94M$6.73M$6.72M
Current liabilities$4.53M$3.76M$6.34M$3.56M$8.79M$3.56M$2.35M$2.37M
Total liabilities$7.95M$7.08M$9.67M$6.99M$10.82M$7.29M$5.17M$6.22M
Shareholders' equity$13.92M$18.73M$17.63M-$37,000$1.76M$1.80M$1.70M$641,000
Shares outstanding26.41M25.40M14.90M10.77M10.54M10.14M9.93M9.42M
Cash flow statement
Operating cash flow-$5.50M-$6.68M-$4.57M-$6.03M-$3.85M-$3.75M-$4.32M-$4.59M
Capital expenditure$3,000$28,000$25,000$0$13,000$46,000$0$5,000
Free cash flow-$5.50M-$6.71M-$4.59M-$6.03M-$3.86M-$3.80M-$4.32M-$4.59M
Investing cash flow-$3,000-$28,000-$25,000$0-$13,000-$46,000$0-$5,000
Financing cash flow$1.88M$5.20M$26.06M$481,000$6.44M$5.57M$4.92M$5.03M
Depreciation & amortization$19,000$36,000$0$51,000$0$0$0-$38,000
Stock-based compensation$1.07M$1.05M$1.08M$948,000$999,000$890,000$956,000$988,000

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.